ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1952

Anti-MDA5 Associated Dermatomyositis: Clinical Features and Outcomes in a Predominantly African-American Case Series

David Wang1, Arezou Khosroshahi2 and Prateek Gandiga2, 1Emory University School of Medicine, Atlanta, GA, 2Emory University, Atlanta, GA

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, dermatomyositis, interstitial lung disease, race/ethnicity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1945–1972) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Individuals with autoantibodies against melanoma differentiation-associated protein 5 (MDA-5) are reported to have a significant risk of developing rapidly progressive and fatal interstitial lung disease (ILD) in clinically amyopathic dermatomyositis patients (CADM). Previous cohort studies of dermatomyositis patients who have been evaluated for the presence of anti-MDA5 antibodies and associated clinical features and outcomes have been largely performed in the Asian, generally Japanese population, or Caucasian patients in North American studies. Few studies have examined MDA5 manifestations in non-Asian subjects. Available reports suggest rates of CADM and ILD may be lower in Caucasian predominant MDA5 cohorts compared to Japanese or Chinese groups. Additionally, association between rapidly progressive interstitial lung disease (RP-ILD) and MDA5 was variable in these North American studies. The goal of this study is to describe the clinical findings and outcomes of a pre-dominantly black cohort in anti-MDA5 associated ILD and the rapidly progressive variant.

Methods: This retrospective case series identified 17 patients with CADM who had anti-MDA5 autoantibodies. Clinical characteristics, high-resolution computed tomography data, lab test results, presence of additional myositis autoantibodies (MAAs), and response to therapy and treatment outcomes were compared between 2 subgroups: black and non-black patients.

Results: Among 17 patients with CADM and anti-MDA 5 autoantibodies, 15 (88%) developed ILD with 6 patients (40%) having the rapidly progressive variant. All 6 patients with RP-ILD presented in the black sub-group. Out of the pre-dominantly black cohort (11 of 17 patients), 6 (55%) patients had at least one additional MAA. Within the black cohort, 5 patients were positive for ANA, 1 for anti-CCP, 3 for anti-SSA, 5 for anti-Ro52, and 1 for anti-synthetase antibodies. Black patients exhibited a higher prevalence of MAAs when compared to the non-black cohort. Average ferritin levels in black (951±2043) and non-black (976±805) patients were both elevated. Average values of CPK, aldolase, ferritin, FVC, and TLC did not differ significantly between black and non-black patients, but the majority of patients with anti-MDA5 antibody alone (4 of 5) developed ILD but not RP-ILD. Three out of four patients who died developed RP-ILD and all four had additional MAAs.

Conclusion: Black patients with anti-MDA5 positive DM exhibited many of the key phenotypic findings in other MDA5 positive DM populations. However, in our cohort, there was a notably increased incidence of RP-ILD and mortality among Black patients compared to non-Black patients. These potential phenotypic variations should be explored further as they can have implications for appropriate evaluation and treatment. Anti-MDA5 positive patients with CADM who are black have a higher prevalence of co-existent MAAs portending a poorer prognosis and a potentially greater predilection of developing RP-ILD than their non-black counterparts. Patients with anti-MDA5 antibodies alone generally have milder forms of ILD whereas coexistent MAAs serve as a possible marker for less favorable prognoses in anti-MDA5 positive patients.

Supporting image 1

Comparison of Clinical Manifestations between Black and non-Black patients

Supporting image 2

Serological Profile, HRCT characteristics


Disclosures: D. Wang: None; A. Khosroshahi: Horizon Therapeutics, 1, 2; P. Gandiga: None.

To cite this abstract in AMA style:

Wang D, Khosroshahi A, Gandiga P. Anti-MDA5 Associated Dermatomyositis: Clinical Features and Outcomes in a Predominantly African-American Case Series [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/anti-mda5-associated-dermatomyositis-clinical-features-and-outcomes-in-a-predominantly-african-american-case-series/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-mda5-associated-dermatomyositis-clinical-features-and-outcomes-in-a-predominantly-african-american-case-series/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology